Ownership and insider activity for RxSight, Inc. (RXST): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets.
Price
| Price | $5.40 |
| Market Cap | $224M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Weinberg Eric | M-Exempt | 35,168 | $153K |
| 2026-09-15 | Weinberg Eric | M-Exempt | 35,168 | $153K |
| 2026-09-05 | Wilterding Mark | A-Award | 258,770 | $1.6M |
| 2026-09-05 | Wilterding Mark | D-Return | 258,770 | $2.6M |
| 2026-09-05 | Weinberg Eric | A-Award | 93,984 | $599K |
| 2026-09-05 | Weinberg Eric | A-Award | 82,608 | $527K |
| 2026-09-05 | Weinberg Eric | A-Award | 65,742 | $419K |
| 2026-09-05 | Weinberg Eric | A-Award | 59,483 | $379K |
| 2026-09-05 | Weinberg Eric | A-Award | 32,258 | $206K |
| 2026-09-05 | Weinberg Eric | D-Return | 95,000 | $1.4M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.0M | $14.0M | $24.4M | $11.8M | $9.7M | $16.7M | $19.9M |
| Short-term Investments | $72.7M | $55.0M | $135.0M | $94.0M | $117.5M | $220.5M | $208.2M |
| Receivables | $789000 | $2.9M | $4.9M | $11.0M | $20.3M | $30.1M | $23.4M |
| Inventory | $7.2M | $8.3M | $8.0M | $14.8M | $17.4M | $22.0M | $31.6M |
| Total Current Assets | $90.2M | $81.5M | $176.3M | $134.6M | $168.4M | $293.8M | $287.5M |
| Property, Plant & Equipment | $19.2M | $18.6M | $15.5M | $14.1M | $13.3M | $23.6M | $23.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $110.4M | $100.7M | $192.7M | $150.2M | $182.6M | $318.6M | $311.8M |
| Accounts Payable | $2.2M | $1.1M | $1.7M | $2.6M | $3.9M | $4.5M | $5.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $974000 | 0 |
| Total Current Liabilities | $8.5M | $11.6M | $11.1M | $17.2M | $20.9M | $25.9M | $26.3M |
| Long-term Debt | 0 | $24.4M | $39.8M | $40.2M | 0 | 0 | $9.9M |
| Total Liabilities | $415.0M | $398.2M | $54.5M | $60.3M | $22.2M | $37.3M | $36.1M |
| Retained Earnings | -$419.9M | -$430.6M | -$479.3M | -$546.0M | -$594.6M | -$622.1M | -$661.0M |
| Total Equity | -$304.6M | -$297.5M | $138.2M | $89.9M | $160.4M | $281.2M | $275.7M |
| Total Debt | $5.5M | $30.8M | $44.9M | $45.0M | $3.0M | $12.3M | $11.0M |
| Net Debt | -$75.2M | -$38.2M | -$114.4M | -$60.8M | -$124.2M | -$224.9M | -$217.1M |
| Working Capital | $81.7M | $69.9M | $165.2M | $117.3M | $147.5M | $267.9M | $261.2M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 4.07 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 5.08 |
Profitability
| Return on Equity | -17.35% |
| Return on Invested Capital | -20.12% |
| Return on Assets | -13.31% |
| Gross Margin | 77.50% |
| Operating Margin | -43.20% |
| Net Margin | -36.80% |
Related companies: BFLY · CERS · DCTH · DMAC · KIDS · NPCE · SMLR
Explore sector: Healthcare · Medical - Devices
More sections of RXST: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks